Failure of danaparoid anticoagulation for cardiopulmonary bypass.
Ariano
R E
RE
Department of Pharmacy, St Boniface General Hospital, Winnipeg, Manitoba, Canada. rariano@gwmail.sbgh.mb.ca
Bhattacharya
S K
SK
Moon
M
M
Brownell
L G
LG
D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy / Q000209:etiology; D000925:Anticoagulants / Q000627:therapeutic use*; D002315:Cardiopulmonary Bypass; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D003327:Coronary Disease / Q000150:complications / Q000601:surgery*; D003871:Dermatan Sulfate / Q000627:therapeutic use*; D004338:Drug Combinations; D006493:Heparin / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D012086:Reoperation; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy; D013927:Thrombosis / Q000139:chemically induced / Q000188:drug therapy; D017211:Treatment Failure
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006493:Heparin; D006497:Heparan Sulfate; C035838:danaparoid